AGL vs. LLAI, PRM, YGEN, VRCI, ABDX, GENI, GDR, DXRX, MED, and VLG
Should you be buying ANGLE stock or one of its competitors? The main competitors of ANGLE include LungLife AI (LLAI), Proteome Sciences (PRM), Yourgene Health (YGEN), Verici Dx (VRCI), Abingdon Health (ABDX), GENinCode (GENI), genedrive (GDR), Diaceutics (DXRX), Intelligent Ultrasound Group plc (MED.L) (MED), and Venture Life Group (VLG). These companies are all part of the "medical" sector.
ANGLE vs.
LungLife AI (LON:LLAI) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
ANGLE received 180 more outperform votes than LungLife AI when rated by MarketBeat users.
ANGLE's return on equity of -44.84% beat LungLife AI's return on equity.
LungLife AI has higher earnings, but lower revenue than ANGLE. LungLife AI is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.
42.3% of LungLife AI shares are owned by institutional investors. Comparatively, 32.4% of ANGLE shares are owned by institutional investors. 62.6% of LungLife AI shares are owned by insiders. Comparatively, 10.8% of ANGLE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, ANGLE had 1 more articles in the media than LungLife AI. MarketBeat recorded 1 mentions for ANGLE and 0 mentions for LungLife AI. LungLife AI's average media sentiment score of 0.67 beat ANGLE's score of 0.00 indicating that ANGLE is being referred to more favorably in the news media.
ANGLE has a consensus target price of GBX 120, indicating a potential upside of 666.19%. Given LungLife AI's higher probable upside, analysts plainly believe ANGLE is more favorable than LungLife AI.
LungLife AI has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
Summary
ANGLE beats LungLife AI on 9 of the 15 factors compared between the two stocks.
Get ANGLE News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools